title: Clinical efficacy of azithromycin for male nongonococcal urethritis.
abstract: The aim of this study was to confirm the clinical efficacy of a single-dose azithromycin (AZM) regimen (1000 mg) for patients with nongonococcal urethritis in real-life practice. The study finally evaluated 55 patients, 42 who were symptomatic and 13 who were asymptomatic, after excluding 40 who visited clinics only once. Sixteen of the symptomatic patients were diagnosed as having nongonococcal chlamydial urethritis, 7 as having nongonococcal nonchlamydial urethritis, and 19 as having urethritis without any microbial detection. Chlamydia trachomatis was detected in 11 asymptomatic patients, Mycoplasma genitalium in 1, and Ureaplasma urealyticum in 1. Of the patients who were microbiologically evaluated before and after single-dose AZM, microbiological cure was achieved in 87% (20/23) of those with symptomatic nongonococcal urethritis and in 100% (13/13) of those with asymptomatic nongonococcal urethritis. The clinical cure rate was 86% for the 42 symptomatic patients with detectable and undetectable pathogens. There were adverse events in 5 (9%) patients but they were commonly mild and self-limited. In conclusion, the single-dose AZM regimen was well tolerated and eradicated the estimated and potential pathogens of nongonococcal urethritis.
authors.affiliation: Department of Urology, Sapporo Medical University School of Medicine, S. 1, W, 16, Chuo-Ku, Sapporo, 060-8543, Japan. stakahas@sapmed.ac.jp
authors.forename: Satoshi
authors.initials: S
authors.lastname: Takahashi
authors.forename: Masanori
authors.initials: M
authors.lastname: Matsukawa
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Kurimura
authors.forename: Koh
authors.initials: K
authors.lastname: Takeyama
authors.forename: Yasuharu
authors.initials: Y
authors.lastname: Kunishima
authors.forename: Akihiko
authors.initials: A
authors.lastname: Iwasawa
authors.forename: Mikio
authors.initials: M
authors.lastname: Koroku
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Tanda
authors.forename: Nobukazu
authors.initials: N
authors.lastname: Suzuki
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Takagi
authors.forename: Takaoki
authors.initials: T
authors.lastname: Hirose
authors.forename: Masahiro
authors.initials: M
authors.lastname: Nishimura
authors.forename: Taiji
authors.initials: T
authors.lastname: Tsukamoto
mesh_terms: D000328:Adult; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D002690:Chlamydia Infections / Q000188:drug therapy / Q000382:microbiology; D002692:Chlamydia trachomatis / Q000187:drug effects; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D009175:Mycoplasma Infections / Q000188:drug therapy / Q000382:microbiology; D045704:Mycoplasma genitalium / Q000187:drug effects; D016896:Treatment Outcome; D016869:Ureaplasma Infections / Q000188:drug therapy / Q000382:microbiology; D016990:Ureaplasma urealyticum / Q000187:drug effects; D014526:Urethritis / Q000188:drug therapy* / Q000382:microbiology; D055815:Young Adult
chemical_list: D000900:Anti-Bacterial Agents; D017963:Azithromycin